GALECTIN THERAPEUTICS INC Share Price Today: Live Updates & Key Insights

GALECTIN THERAPEUTICS INC share price today is $2.75, up -1.79%. The stock opened at $2.8 against the previous close of $2.8, with an intraday high of $2.82 and low of $2.735.

GALECTIN THERAPEUTICS INC Share Price Chart

GALECTIN THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
us-stock

GALECTIN THERAPEUTICS INC Share Price Performance

$2.75 -0.0179(-1.79%) GALT at 23 Mar 2026 01:15 PM Biotechnology
Lowest Today 2.735
Highest Today 2.82
Today’s Open 2.8
Prev. Close 2.8
52 Week High 7.13
52 Week Low 1.12
Day’s Range: Low 2.735 High 2.82
52-Week Range: Low 1.12 High 7.13
1 day return -
1 Week return -12.81
1 month return -9.67
3 month return -31.63
6 month return -43.83
1 year return +67.98
3 year return +38.44
5 year return +22.99
10 year return -

GALECTIN THERAPEUTICS INC Institutional Holdings

Vanguard Group Inc 3.55

Vanguard Total Stock Mkt Idx Inv 2.10

Advisor Group Holdings, Inc. 1.69

BlackRock Inc 1.24

Marshall Wace Asset Management Ltd 0.93

Geode Capital Management, LLC 0.93

Vanguard Institutional Extnd Mkt Idx Tr 0.87

Sontag Advisory LLC 0.74

Commonwealth Equity Services Inc 0.52

LPL Financial Corp 0.50

Susquehanna International Group, LLP 0.45

Fidelity Extended Market Index 0.43

Geneos Wealth Management Inc 0.38

Millennium Management LLC 0.37

State Street Corp 0.36

Morgan Stanley - Brokerage Accounts 0.35

Sovran Advisors, LLC 0.35

Vivaldi Capital Management, LLC 0.32

Jane Street Group LLC 0.31

RETIREMENT GUYS FORMULA LLC 0.26

683 Capital Management LLC 0.25

Wellington Management Company LLP 0.22

Blackrock Extended Mkt Fund CF 0.20

CAMBRIDGE Invest RESEARCH ADVISORS, INC. 0.20

iShares Micro-Cap ETF 0.18

Extended Equity Market Fund K 0.17

Fidelity Total Market Index 0.15

Fidelity Series Total Market Index 0.11

Spartan Extended Market Index Pool F 0.10

NT Ext Equity Mkt Idx Fd - L 0.10

Northern Trust Extended Eq Market Idx 0.08

Horizon Kinetics Medical ETF 0.08

NT Ext Equity Mkt Idx Fd - NL 0.08

Fidelity Nasdaq Composite Index 0.07

Spartan Total Market Index Pool G 0.06

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.06

Vanguard Instl Ttl Stck Mkt Idx Tr 0.06

Schwab Total Stock Market Index 0.05

Vanguard Balanced Index Inv 0.04

Vanguard Instl Ttl Stk Mkt Idx InstlPls 0.04

GALECTIN THERAPEUTICS INC Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

GALECTIN THERAPEUTICS INC Fundamentals

Market Cap 177.32 M

PB Ratio 207.6975

PE Ratio 0.0

Enterprise Value 291.80 M

Total Assets 17.50 M

Volume 147639

GALECTIN THERAPEUTICS INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-41703000 -41.7M, FY22:-39200000 -39.2M, FY21:-30975000 -31.0M, FY20:-23516000 -23.5M, FY19:-13381000 -13.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-2000 -0.0M, Q1/2025:-10000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-9000 -0.0M

Quarterly Net worth Q3/2025:-8183999 -8.2M, Q2/2025:-7521000 -7.5M, Q1/2025:-9631000 -9.6M, Q3/2024:-11220000 -11.2M, Q2/2024:-12371000 -12.4M

About GALECTIN THERAPEUTICS INC & investment objective

Company Information Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Organisation Biotechnology

Employees 15

Industry Biotechnology

CEO Mr. Joel Lewis CPA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

GALECTIN THERAPEUTICS INC FAQs

What is the share price of GALECTIN THERAPEUTICS INC today?

The current share price of GALECTIN THERAPEUTICS INC is $2.75.

Can I buy GALECTIN THERAPEUTICS INC shares in India?

Yes, Indian investors can buy GALECTIN THERAPEUTICS INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy GALECTIN THERAPEUTICS INC shares in India?

You can easily invest in GALECTIN THERAPEUTICS INC shares from India by:

Can I buy fractional shares of GALECTIN THERAPEUTICS INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of GALECTIN THERAPEUTICS INC?

GALECTIN THERAPEUTICS INC has a market cap of $177.32 M.

In which sector does GALECTIN THERAPEUTICS INC belong?

GALECTIN THERAPEUTICS INC operates in the Biotechnology sector.

What documents are required to invest in GALECTIN THERAPEUTICS INC stocks?

To invest, you typically need:

What is the PE and PB ratio of GALECTIN THERAPEUTICS INC?

The PE ratio of GALECTIN THERAPEUTICS INC is N/A and the PB ratio is 207.70.